The Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets, and is modular, allowing the design of multimeric Anticalin based bi- and multi-specific proteins. The clinical pipeline consists of immuno-oncology programs including S095012, SGN-BB228, and BOS-342 in partnership with collaborators.
Cyborg Score Rationale
Pieris Pharmaceuticals has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. The company is clinical-stage with multiple promising bispecific programs, though still pre-commercial.
Top Insights
Recently upgraded to Zacks Rank #1 (Strong Buy) by analysts
Multiple immuno-oncology bispecific programs in clinical development with Seagen and other collaborators
Platform-focused approach with modular Anticalin technology enabling multi-target bispecific design
Clinical-stage company with pipeline spanning immuno-oncology, respiratory, and anemia
Named Competitors
4-1BB Bispecific Programs — Co-development partner on CD228 x 4-1BB program